Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to 0.45%.

  • Spyre Therapeutics' Return on Capital Employed rose 700.0% to 0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.5% for FY2024, which is 8900.0% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Return on Capital Employed is 0.45%, which was up 700.0% from 0.45% recorded in Q2 2025.
  • Spyre Therapeutics' Return on Capital Employed's 5-year high stood at 2.56% during Q2 2023, with a 5-year trough of 1.61% in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' median Return on Capital Employed value was 0.62% (recorded in 2021), while the average stood at 0.59%.
  • Per our database at Business Quant, Spyre Therapeutics' Return on Capital Employed soared by 36700bps in 2023 and then tumbled by -29200bps in 2024.
  • Spyre Therapeutics' Return on Capital Employed (Quarter) stood at 0.66% in 2021, then plummeted by -92bps to 1.27% in 2022, then grew by 21bps to 1.0% in 2023, then soared by 55bps to 0.45% in 2024, then increased by 1bps to 0.45% in 2025.
  • Its Return on Capital Employed stands at 0.45% for Q3 2025, versus 0.45% for Q2 2025 and 0.41% for Q1 2025.